Alector Inc (ALEC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.91 (+3.24%), Market cap $0.24B, 52-week low–high $1.14 ~ $3.32.
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Al
Financial statements, price targets, institutional (13F) holdings and related news for Alector Inc are updated in real time on BlackAll Trade.
Alector Inc trades at $1.91 (+3.24%). Real-time quotes and charts are available on BlackAll Trade.
Alector Inc has a market cap of about $0.24B.
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational